On #2: Andy Grove once said “abandoning today's 'commodity' manufacturing can lock you out of tomorrow's emerging industry” and nowhere is this more true than in pharma and life sciences. Over the last 20 years we have shifted much of the drug discovery process to large Chinese contract research organizations (CROs) like Wuxi—a company which was added to the DoW’s list of “Chinese military companies” in June. We’ve seen this multiple times now. When the work moves overseas, the expertise and infrastructure follow. We're at risk of losing the ability to turn our ideas into medicines. That’s an unacceptable dependency for something so central to our health and our future.